University of Sussex
Browse
ciab162.pdf (5.32 MB)

High-dose oral and intravenous rifampicin for the treatment of tuberculous meningitis in predominantly Human Immunodeficiency Virus (HIV)-positive Ugandan adults: a phase II open-label randomized controlled trial

Download (5.32 MB)
journal contribution
posted on 2023-06-10, 03:43 authored by Fiona CresswellFiona Cresswell, David B Meya, Enock Kagimu, Daniel Grint, Lindsey Te Brake, John Kasibante, Emily Martyn, Morris Rutakingirwa, Carson M Quinn, Micheal Okirwoth, Lillian Tugume, Kenneth Ssembambulidde, Abdu K Musubire, Ananta S Bangdiwala, Allan Buzibye, Conrad Muzoora, Elin M Svensson, Rob Aarnoutse, David R Boulware, Alison M Elliott
Background High-dose rifampicin may improve outcomes of tuberculous meningitis (TBM). Little safety or pharmacokinetic (PK) data exist on high-dose rifampicin in human immunodeficiency virus (HIV) coinfection, and no cerebrospinal fluid (CSF) PK data exist from Africa. We hypothesized that high-dose rifampicin would increase serum and CSF concentrations without excess toxicity. Methods In this phase II open-label trial, Ugandan adults with suspected TBM were randomized to standard-of-care control (PO-10, rifampicin 10 mg/kg/day), intravenous rifampicin (IV-20, 20 mg/kg/day), or high-dose oral rifampicin (PO-35, 35 mg/kg/day). We performed PK sampling on days 2 and 14. The primary outcomes were total exposure (AUC0–24), maximum concentration (Cmax), CSF concentration, and grade 3–5 adverse events. Results We enrolled 61 adults, 92% were living with HIV, median CD4 count was 50 cells/µL (interquartile range [IQR] 46–56). On day 2, geometric mean plasma AUC0–24hr was 42.9·h mg/L with standard-of-care 10 mg/kg dosing, 249·h mg/L for IV-20 and 327·h mg/L for PO-35 (P < .001). In CSF, standard of care achieved undetectable rifampicin concentration in 56% of participants and geometric mean AUC0–24hr 0.27 mg/L, compared with 1.74 mg/L (95% confidence interval [CI] 1.2–2.5) for IV-20 and 2.17 mg/L (1.6–2.9) for PO-35 regimens (P < .001). Achieving CSF concentrations above rifampicin minimal inhibitory concentration (MIC) occurred in 11% (2/18) of standard-of-care, 93% (14/15) of IV-20, and 95% (18/19) of PO-35 participants. Higher serum and CSF levels were sustained at day 14. Adverse events did not differ by dose (P = .34). Conclusions Current international guidelines result in sub-therapeutic CSF rifampicin concentration for 89% of Ugandan TBM patients. High-dose intravenous and oral rifampicin were safe and respectively resulted in exposures ~6- and ~8-fold higher than standard of care, and CSF levels above the MIC.

History

Publication status

  • Published

File Version

  • Published version

Journal

Clinical Infectious Diseases

ISSN

1058-4838

Publisher

Oxford University Press

Issue

5

Volume

73

Page range

876-884

Event location

United States

Department affiliated with

  • Global Health and Infection Publications

Full text available

  • Yes

Peer reviewed?

  • Yes

Legacy Posted Date

2022-05-27

First Open Access (FOA) Date

2022-05-27

First Compliant Deposit (FCD) Date

2022-05-27

Usage metrics

    University of Sussex (Publications)

    Categories

    No categories selected

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC